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In the 100 years since the death of George Huntington in
1916, the disorder he described as a ‘medical curiosity’ has
become a focus of intense medical and scientiﬁc interest, in
part because of the contribution of families in generating
knowledge about this family disease. As many writers have
noted, George Huntington’s own family played a crucial
role in deﬁning this illness (Harper, 2002). What has
been less appreciated is that the affected families he
described also played a role, in ways that George
Huntington himself acknowledged. Not quite 22 years
old (Fig. 1), just graduated from the College of Physicians
and Surgeons in New York City, and with little clinical
experience, no established medical practice, and no patients
of his own with the disorder, he wrote an account in 1872
that William Osler considered one of the most succinct and
accurate portraits of a disease ever written (Osler, 1893). It
was not the earliest medical account of hereditary chorea
but it was certainly the most complete. And for social and
cultural as well as medical and scientiﬁc reasons, it played a
far more important role in deﬁning the discrete clinical
entity that soon came to be known as ‘Huntington’s
chorea’ and by the late 1960s, as ‘Huntington’s disease’.
Despite considerable recognition during his lifetime, George
Huntington remained a small town family physician but
not a provincial or isolated one. He was aware that his
paper had drawn the attention of the medical profession
at home and abroad and that this had helped reveal the
disease in many parts of the world. He was in touch with
some eminent clinicians of his day, including Osler, and an
invited speaker on Huntington’s chorea at medical societies
such as the inﬂuential New York Neurological Society. At a
time when medicine was becoming increasingly ‘scientiﬁc’,
he too placed his hope in research, although he chose not
to pursue research himself. Alluding to the unknown path-
ology of chorea, which had intrigued him from the start, he
trusted ‘that science, which has accomplished such wonders
through the never-tiring devotion of its votaries, may yet
“overturn and overturn, and overturn it,” until it is laid
open to the light of day’. (Huntington, 1872).
A tale of two families
On 12 June 1806, in the long-established farming and ﬁsh-
ing village of East Hampton, at the far eastern end of Long
Island, about 60 miles northeast of New York City, USA
(Fig. 2), Captain David Hedges, a member of the local
gentry, awoke to ﬁnd his wife missing. A search ‘thro
ﬁelds of grain to the shore’ did not ﬁnd her ‘and there is
every reason to believe she has precipitated herself into the
surf’, reported the local newspaper. ‘Mrs. Hedges was
about 40 years of age, and was much esteemed by her
neighbors’ the obituary continued. ‘This extraordinary
step is attributed to her extreme dread of the disorder
called St. Vitus’ dance, with which she began to be affected,
and which her mother now has to a great degree. From
some arrangements of her clothing it appears she had for
some time contemplated her melancholy end.’ (The Suffolk
Gazette, 30 June 1806).
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Phebe Hedges and her mother, also called Phebe, des-
cended from one of the oldest and most prominent East
Hampton families who had settled the town in the 17th
century from New England. [They bore no known relation
to the East Anglia families whom P. R. Vessie and
M. Critchley later and erroneously characterized as disrep-
utable ancestors of many Huntington’s families in the USA
(Wexler, 2008)]. They were patients of George
Huntington’s grandfather, known as the Honourable Abel
Huntington (1777–1858), a highly respected physician who
had arrived in East Hampton from Connecticut in 1797
and found the disease well established there. The
Huntingtons were long considered relative newcomers but
they quickly won the esteem of their neighbours and played
active roles in the local community, state, and even nation-
ally. When Abel’s political activities drew him away from
East Hampton, his physician son, George Lee Huntington
(1811–81), became the doctor to the descendants of Phebe
and Captain David Hedges. George Huntington, the son of
George Lee and his wife Mary, born in 1850 and educated
in East Hampton, was thus a third generation physician in
a medical family that had lived alongside families with her-
editary chorea since the end of the 18th century and was
well situated to observe, over multiple generations, who did
and did not have the disease.
‘A medical curiosity’
In the fall of 1871, soon after graduation from medical
school, George Huntington moved to Pomeroy, Ohio. His
cousin had married a clergyman in Pomeroy and suggested
the young George open a medical practice there. Invited to
present a paper to the local Meigs and Middleport
Academy of Medicine in nearby Middleport, he chose to
talk ‘On Chorea’, perhaps because he had recently
observed cases of childhood (Sydenham’s) chorea in the
clinic as a medical student in New York City and was
struck by the differences from the chorea he had observed
back home. Most of the paper, in fact, described this
common type of chorea but in the ﬁnal paragraphs
George Huntington outlined three predominant character-
istics of a type of chorea he believed to be present ‘exclu-
sively on the east end of Long Island’. First was its
hereditary nature, for it was ‘conﬁned to certain and for-
tunately a few families, and has been transmitted to them,
an heirloom from generations away back in the dim past’.
It differed, however, ‘from the general laws of so-called
hereditary diseases’ in which the disease may skip a gener-
ation. ‘Unstable and whimsical as the disease may be in
other respects, in this it is ﬁrm, it never skips a generation
to again manifest itself in another; once having yielded its
claims, it never regains them.’
Second, was the tendency to what George Huntington
called, in 19th century parlance, ‘insanity, and sometimes
that form of insanity which leads to suicide’. (19th century
meanings of ‘insanity’ ranged from disturbances of mood to
Figure 1 George Huntington c. 1868. (Mulfold Album,
Courtesy of the East Hampton Library, Pennypacker Long Island
Collection). A naturalist as well as a hunter despite his severe
asthma, George Huntington also sketched and painted landscapes
and local scenes all his life, a practice that no doubt contributed to
his keen powers of observation. His travel reports, published in a
Long Island newspaper, testify to his early skill as a writer.
Figure 2 Map of Connecticut and environs, c. 1780.
Including East Hampton (white arrow) [H. Klockhoff and B. Romans,
‘Connecticut and Parts Adjacent‘ (Amsterdam: Covens and Mortier
and Covens Jur., 1780) Library of Congress, Geography and Map
Division].
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disorders of thought and behaviour as well as personality
changes. Suicide typically cast the deceased as having suf-
fered from insanity.) He also noted speciﬁcally the tendency
to cognitive impairment. ‘As the disease progresses the
mind becomes more or less impaired, in many amounting
to insanity, while in others mind and body both gradually
fail until death relieves them of their sufferings’. He further
described a lack of self-awareness and loss of inhibitions on
the part of sufferers, offering a far more nuanced descrip-
tion than had been given in earlier accounts.
Finally, he noted that the symptoms generally manifested
in adult life, most often between 30 and 40 years of age,
increasing very gradually ‘until every muscle in the body
becomes affected (excepting the involuntary ones)’. The dis-
ease progressed inexorably without any periods of remission.
‘When once it begins it clings to the bitter end.’ Huntington
ended by acknowledging that he knew nothing of its path-
ology and offered his account, ‘not that I considered it of
any great practical importance to you, but merely as a med-
ical curiosity, and as such it may have some interest’.
It is sometimes assumed that the East Hampton families
with chorea were George Huntington’s patients. In fact,
George himself never established a medical practice in East
Hampton, although he tried to brieﬂy in the summer of 1872.
The cases he described were patients of his father and grand-
father (Fig. 3) and he always acknowledged his debt to them,
indicating that without their facts and observations his paper
could not have been written (Osler, 1893). (The Huntington
household, in fact, included a number of educated, acute
observers whose intimate local knowledge was shared with
the young George—apart from his parents, there was
George’s aunt, the poet and novelist Cornelia Huntington
who published a novel ﬁlled with allusions to ‘the sins of
the fathers’ and with a ‘nervous’ central character; also their
long-time boarder John Wallace, an educated Scottish church-
man who founded the local Episcopal church.)
But he also incorporated the knowledge of the East
Hampton families themselves, including their recognition
that this malady was hereditary. Actually many ailments
were considered to be inherited in the 19th century. It is
not surprising that, in an old community with memory
going back many generations, the affected families—indeed
the entire community—recognized that this disorder was
hereditary. Nor is it surprising that they theorized about
its genealogical origins and even spoke of families ‘who be-
longed to the disease’. What surprises is that they were
expert diagnosticians who had precise ideas of who did or
did not have this illness in each generation. They understood
its terrors, for as George Huntington wrote, ‘it is spoken of
by those in whose veins the seeds of the disease are known
to exist, with a kind of horror, and not at all alluded to
except through dire necessity, when it is mentioned as “that
disorder”’. (According to Henry P. Hedges, a distant relative
of Phebe Hedges and a historian of East Hampton, it was
also called St. Vitus’s dance although ‘the subject is avoided
by most people as distasteful’.) The families also understood
its trajectory, for ‘its end is so well known to the sufferer and
his friends, that medical advice is seldom sought’. Years after
Figure 3 Pages from the ledgers and daybooks of George Huntington’s grandfather Abel (A) and father George Lee (B) who
cared for the families whose illness George later described (Courtesy of the East Hampton Library, Pennypacker Long Island
Collection). See Supplementary material for further references.
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he published ‘On Chorea’, George Huntington the artist as
well as the physician beautifully captured both his own
childhood awe on ﬁrst encountering persons with chorea
and his empathy as an adult for the suffering of those
who had been his family’s neighbours and friends:
‘Driving with my father through a wooded road leading from
East Hampton to Amagansett, we suddenly came upon two
women, mother and daughter, both tall, thin, almost
cadaverous, both bowing, twisting, grimacing. I stared in won-
derment, almost in fear. What could it mean? My father
paused to speak with them, and we passed on. Then my
Gamaliel like instruction began; my medical education had
its inception. From this point my interest in the disease has
never wholly ceased. Then came the hanging of D.H. in his
blacksmith shop. He was a victim of incipient chorea, knew it,
possibly had been waiting for it, the “Sanctus Invictus,” and
well knowing the character of the foe he must meet, the so
dreaded, the long expected, the conquering, he cut short the
taper and his life went out. Other victims had sought the same
refuge again and again by drowning. Others, of a different
nervous organization perhaps, lived on if not content, still
seemingly reconciled to Fate, until mind and body both ex-
hausted they fell asleep.’
Huntington’s chorea in the
crosshairs of psychiatry, neu-
rology, genetics and eugenics
Although George Huntington’s paper was immediately
published in a reputable Philadelphia medical journal,
The Medical and Surgical Reporter (Fig. 4), it attracted
little notice at ﬁrst apart from a brief abstract in Virchow
and Hirsch’s Jahresbericht or Yearbook of Important
Medical Writings for the Year 1872. Two years later, the
eminent Italian neuropathologist Camillo Golgi footnoted it
in a paper noting dramatic changes in the cortex and stri-
atum of a deceased 42-year-old male patient with chorea,
mental disturbance, and an ‘hysteric’ mother (Golgi, 1874).
However, with the expansion of neurology as a medical
specialty in the 1870s and 1880s and the growing popula-
tion of patients in psychiatric hospitals and asylums in the
USA and Europe, clinicians began reporting similar cases
with increasing frequency. In 1892 some authors were even
claiming that the literature on this disorder was ‘copious’
and that its clinical history was ‘very thoroughly known’.
(Osler, 1893; Wexler, 2008). (A few clinicians, including
Charcot, considered ‘hereditary chorea’ a variant of the
childhood disorder. But by the 1890s most viewed it as
distinct.) Ironically, while neurologists claimed
Huntington’s chorea as a neurological disease par excel-
lence, many more psychiatrists than neurologists actually
encountered such patients, typically in the mushrooming
population of psychiatric institutions. Those who did
were impressed by the contrast this disorder presented
with Sydenham’s chorea, including the late onset, the inex-
orable progression, and the fact that ‘heredity is one of the
most remarkable features’. Nonetheless, the names used at
the time highlighted features other than heredity, for ex-
ample chorea of the aged, choreic dementia, dementia chor-
eica, and Osler’s preference, chronic progressive chorea,
although soon Huntington’s chorea displaced them all
(Wexler, 2008).
Figure 4 George Huntington’s 1872 paper ‘On chorea’ in the Medical and Surgical Reporter. His later talks before various medical
societies on Huntington’s chorea were published, in the Brooklyn Medical Journal (1895), the Transactions of the Tri-State Medical Association (1903),
and The Journal of Nervous and Mental Disease (1910). His unpublished papers are in the Special Collections of the Columbia University Health
Sciences Library, New York City, and the Pennypacker Long Island Collection, East Hampton Library, New York.
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With the rediscovery of Mendel’s laws in 1900 and also the
establishment of eugenics societies in many countries, the her-
editary dimension of Huntington’s chorea—and the speciﬁc
pattern of inheritance—began to draw increased attention,
not only from clinicians but also from biologists studying
Mendelian heredity more broadly. In addition to its interest
as a case study in human Mendelian inheritance,
Huntington’s chorea now appeared to some inﬂuential sup-
porters of eugenics as a cause for public health alarm. With
the resources of the Carnegie-funded Eugenics Record Ofﬁce
at Cold Spring Harbor, New York, the biologist and eugenics
leader Charles B. Davenport in 1911 initiated the ﬁrst large-
scale pedigree study of families with Huntington’s chorea,
creating pedigrees that included some 962 alleged cases,
living and deceased, in a total of 4370 individuals in the
northeastern USA. Davenport and Muncey’s 1916 paper
‘Huntington’s Chorea in Relation to Heredity and
Eugenics’, was widely cited and largely unchallenged for dec-
ades despite Davenport’s extreme eugenic views, which helped
to normalize the notion of sterilization as the recommended
method of prevention, a notion that prevailed well into the
1960s (Davenport and Muncey, 1916). At that time Hans
and Gilmore and later Wexler demonstrated that these pedi-
grees were riddled with unreliable or clearly erroneous diag-
noses and gross genealogical errors, including errors that laid
the foundation for subsequent claims about Huntington’s and
witches, ‘criminality’, and violence (Hans and Gilmore, 1969;
Wexler, 2008). Such claims, repeated even today, deepened
the stigmatization of Huntington’s families while discouraging
research toward effective treatment. They also gave families
further incentives for maintaining secrecy and silence about
this disease (Wexler and Rawlins, 2005).
Scientific advance and social
change
Reports on the neuropathology of chorea in adults ap-
peared as early as the 1870s, with researchers generally
agreed that the basic lesion was located in the basal gang-
lia, with the striatum, particularly the caudate nucleus,
showing the greatest degree of atrophy. However, there
was little agreement on its cause and relatively little pro-
gress for decades. The conﬂuence of several developments
in the 1960s radically transformed this bleak research land-
scape. First, the discovery of L-DOPA and its beneﬁts for
patients with Parkinson’s disease spurred an international
gathering of neurologists in 1967 to organize a Research
Group on Huntington’s Chorea. Second, the rise of social
movements in the 1960s challenged the legacy of eugenics
and encouraged members of families with Huntington’s to
become active on their own behalf. Activists such as the
North Americans Marjorie Guthrie, widow of the song-
writer and singer Woody Guthrie who died with
Huntington’s in 1967, and Milton and Nancy Wexler, hus-
band and daughter of recently diagnosed Leonore Wexler,
along with Ralph Walker in Canada, Mauveen Jones in the
UK, Gerrit Dommerholt in the Netherlands, and
Huntington’s family members elsewhere spearheaded ef-
forts to improve care as well as to interest scientists in
research. In the late 1960s and 1970s they formed disease
advocacy associations in many countries (called self-sup-
port organizations or health voluntary agencies) which,
along with revolutionary advances in molecular genetics
and neuroscience, expanded biomedical interest in
Huntington’s. New technologies of gene mapping opened
up possibilities for identifying—and perhaps disabling—the
aberrant gene. New modes of imaging offered possibilities
for understanding—and potentially intervening in—the se-
quence of pathological changes in the brain.
At a 1972 Centennial Symposium on Huntington’s disease,
in Columbus Ohio, near the town where George Huntington
presented his landmark paper, some 136 researchers and a
few members of Huntington’s families from around the world
gathered to commemorate his contribution and develop new
directions for research. Out of this meeting came the impetus
Figure 5 Huntington special issue of Neurographs. In 1908
the New York neurologist William Browning devoted an entire issue
of his journal Neurographs to Huntington’s chorea, emphasizing what
he called ‘the world-wide interest’ in the disease.
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for a bold collaborative project focused on a unique cluster of
affected families in Venezuela who had been diagnosed back
in the 1950s by a local physician, Americo Negrette, author
of the ﬁrst monograph ever published on Huntington’s dis-
ease (Negrette, 1963). Drawing on the new somatic cell gen-
etics for mapping genes, this project, led by Nancy Wexler,
culminated in 1983 in the identiﬁcation of a genetic marker
for Huntington’s (Gusella et al., 1983). Besides demonstrating
that the new technology could be used for mapping the
human genome, the landmark marker discovery for the ﬁrst
time enabled those at 50% risk for Huntington’s disease to
learn either that they were forever free of the disease and were
not in danger of passing it on to their children or grandchil-
dren, or that they did carry the abnormal version of the gene
and would therefore develop symptoms if they lived long
enough: a momentous form of new knowledge. It also
inspired the formation of the legendary Huntington’s
Disease Collaborative Research Group, again under the lead-
ership of Nancy Wexler and the Hereditary Disease
Foundation. After 10 agonizing years of work, the group
collectively announced the identiﬁcation of the abnormal
Huntington’s disease gene (Huntington’s Disease
Collaborative Research Group, 1993; Wexler, 2012) (Fig. 6).
Towards a third age of
Huntington’s disease
In a coding region of chromosome 4 initially labelled IT-15
(‘interesting transcript 15’), the Collaborative Research Group
had found an expanded CAG triplet repeat that segregated
completely with Huntington’s disease cases. The gene was
soon renamed HTT and its protein product baptized ‘hun-
tingtin’. So began a new age of Huntington’s disease: armed
now with certainty of the cause of every past, present and
future case of Huntington’s disease, researchers could focus
their efforts on understanding the gene, studying the protein
in its wild-type and mutant forms, elucidating the mechanisms
through which mutant huntingtin (mHTT) causes disease, and
working on therapies targeting the mutation and its known
effects.
Hopes that the gene discovery would lead overnight to
a cure for Huntington’s disease quickly sublimated into a real-
ization that a long road lay ahead—but at least, a road illu-
minated by the certitude conferred by the genetic basis of
Huntington’s disease. At every branch-point, paths uncon-
nected to the expanded HTT gene could be discounted. This
certainty offers researchers on Huntington’s a potent advantage
over those studying more common neurodegenerative diseases,
which remain almost entirely idiopathic. Our understanding of
the complex roles of the protein and the multiple toxicities of
its mutant counterpart rapidly burgeoned, but there was solace
to be drawn from knowing each was a potential new target for
therapeutic development (reviewed in Wild and Tabrizi, 2014;
Bate et al., 2015).
The ﬁrst mouse model of Huntington’s disease, the R6/2,
expressing HTT exon 1 under control of the human pro-
moter, followed rapidly in 1996 and remains a mainstay in
the ﬁeld thanks to its robust phenotype and rapid progres-
sion. mHTT-containing protein aggregates were soon
found in its neurons and in the brains of human patients.
Numerous model systems from cells to primates and every-
thing in between are now available to elucidate aspects of
pathology and explore therapeutics (reviewed in Bates
et al., 2015).
The ﬁrst glimmer of tractability came in 2000 from an in-
ducible mouse model in which Yamamoto and colleagues
showed that stopping production of the mutant protein after
Figure 6 Collectively authored paper describing the identification of the CAG triplet repeat expansion in IT15 responsible for
Huntington’s disease. This discovery was considered so momentous that it appeared on the front page of The New York Times (24 March 1993).
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the onset of disability resulted not in the expected slowing of
decline but in a reversal of symptoms and neuropathology
(Yamamoto et al., 2000). Numerous therapeutic successes fol-
lowed in mouse models using small-molecule therapeutics tar-
geting an increasing array of rational cellular targets (Fig. 5).
Many agents have gone on to be tested in human patients,
unfortunately with no success in reversing, delaying or slowing
the progression of Huntington’s disease so far: one patient
sardonically reﬂected to one of us, ‘what we really need is a
pill to turn humans into mice’. So far, most compounds tested
in patients have been ‘neutraceuticals’ or repurposed drugs
from other indications which may in part explain their
poor performance in the complex context of Huntington’s dis-
ease in the human brain (Bates et al., 2015). But things are
changing.
If we could achieve in humans, using a targeted drug
molecule, what was seen in Yamamoto’s conditional HTT
knockout mouse, we would theoretically treat every facet
of Huntington’s disease. Work on such ‘gene silencing’ or
‘huntingtin lowering’ approaches began in Huntington’s
disease model animals in 2005 using RNA interference.
Similar approaches using antisense oligonucleotides
(ASOs)—modiﬁed single-stranded DNA—began around
the same time. Each aims to reduce HTT expression by
targeting its mRNA transcript for removal by the cellular
mRNA degradation machinery. For the past decade these
technologies have been honed and put through their paces
in animal models (Wild and Tabrizi, 2014).
Huntington was almost 22 when he presented his seminal
work, and by coincidence it was 22 years after the discovery
of the HTT gene that the ﬁrst injection of an ASO thera-
peutic targeting huntingtin production in the brain was ad-
ministered into the spinal ﬂuid of a patient with
Huntington’s disease in September 2015 in either
Vancouver or London (the ongoing safety trial remains
double-blinded). Whatever the outcome of this ﬁrst tentative
step, the ‘third age’ of Huntington’s disease—the age of ra-
tionally-developed therapeutics targeting the cause and
known pathobiology of Huntington’s disease—is now at
hand. Crucially, the ASO trial and its successors are em-
powered by biomarkers and outcome measures estab-
lished and validated by thousands of Huntington’s disease
family volunteers who are giving their time and energy to
observational cohort studies knowing they are not likely to
beneﬁt themselves but that many others will.
Conclusion
One hundred years after George Huntington’s death, his
eponymous disease is no longer the obscure and shameful
malady that it was during his lifetime. Nor is it considered
so rare. New studies have shown a much higher prevalence
rate, at least in the UK, than was previously reported,
about 12 per 100 000 population, although the incidence
has remained unchanged (Evans et al., 2013). And while
Figure 7 Overview of current therapeutic targets for Huntington’s disease. From Wild and Tabrizi (2014).
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Huntington’s is still incurable, it is no longer untreatable.
Medications can reduce choreic movements and ease psy-
chiatric symptoms. Social and psychological support can do
much to improve quality of life, for unaffected family mem-
bers as well as for those at risk and those living with the
disease. New technologies such as in vitro fertilization and
preimplantation genetic diagnosis (PGD) offer increased op-
tions for those at risk who wish to have families without
passing on the malady (Bates et al., 2015). The activism
and imagination of Huntington’s family members, espe-
cially the young, has helped reduce the isolation and
social stigma that has long added to the suffering asso-
ciated with the disease. But all these advances are distrib-
uted unequally; many people in Huntington’s families, not
only in poor countries but also in wealthy ones, do not
have access to these beneﬁts. While it is essential that we
continue to invest in research on disease-modifying thera-
pies, it is also vital that existing interventions, therapies and
services be made accessible to those who need them if the
promise of science is truly to be realized.
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